Literature DB >> 18837084

Protective effect of ilomastat on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats.

Ying-De Wang1, Wei Wang.   

Abstract

AIM: To evaluate the protective effects of ilomastat, an exogenous matrix metalloproteinase (MMP) inhibitor, on trinitrobenzenesulfonic acid (TNB)-induced ulcerative colitis (UC) in rats.
METHODS: Male SD rats were randomly divided into model group, protective groups A and B, and normal control group. Rats in the model group received only intra-colonic TNB. Rats in the protective groups A and B received intra-peritoneal ilomastat of 10 mg/kg and 20 mg/kg, respectively, beside TNB. Rats in the normal control group received only intra-colonic normal saline. After 3 wk, segments of colon were obtained. RT-PCR and immunohistochemistry were used to examine the expression of MMP-1 and TIMP-1. Hematoxylin-eosin (HE) staining was used for pathological study.
RESULTS: The model of UC was successfully induced in rats. Inflammation of colonic mucosa greatly improved in protective groups A and B. Expression of MMP-1 and TIMP-1 in the model group, protective groups A and B was significantly higher than that in the normal control group (P < 0.0001) with MMP-1 expression increased more significantly than TIMP-1 expression. Expression of MMP-1 in protective groups A and B was significantly lower than that in the model group (P < 0.0001) . Expression of MMP-1 in protective group B was significantly lower than that in protective group A (P < 0.0001).
CONCLUSION: Ilomastat improves TNB-induced UC in rats by inhibiting the MMP-1 activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18837084      PMCID: PMC2748202          DOI: 10.3748/wjg.14.5683

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  22 in total

Review 1.  Pharmacotherapeutic options in inflammatory bowel disease: an update.

Authors:  Y H Kho; M O Pool; F G Jansman; J W Harting
Journal:  Pharm World Sci       Date:  2001-02

Review 2.  Tissue inhibitors of metalloproteinases: evolution, structure and function.

Authors:  K Brew; D Dinakarpandian; H Nagase
Journal:  Biochim Biophys Acta       Date:  2000-03-07

Review 3.  Matrix metalloproteinases and the gut - new roles for old enzymes.

Authors:  Sylvia L F Pender; Thomas T MacDonald
Journal:  Curr Opin Pharmacol       Date:  2004-12       Impact factor: 5.547

Review 4.  Role of matrix metalloproteinases in inflammatory bowel disease.

Authors:  Yuji Naito; Toshikazu Yoshikawa
Journal:  Mol Aspects Med       Date:  2005 Aug-Oct

5.  A major role for matrix metalloproteinases in T cell injury in the gut.

Authors:  S L Pender; S P Tickle; A J Docherty; D Howie; N C Wathen; T T MacDonald
Journal:  J Immunol       Date:  1997-02-15       Impact factor: 5.422

6.  The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease.

Authors:  A P Sykes; R Bhogal; C Brampton; C Chander; C Whelan; M E Parsons; J Bird
Journal:  Aliment Pharmacol Ther       Date:  1999-11       Impact factor: 8.171

7.  Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in ulcerative colitis.

Authors:  Ying-De Wang; Pei-Yun Yan
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

8.  Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease.

Authors:  R B Heuschkel; T T MacDonald; G Monteleone; M Bajaj-Elliott; J A Smith; S L Pender
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

9.  Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease.

Authors:  B von Lampe; B Barthel; S E Coupland; E O Riecken; S Rosewicz
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

10.  Metalloproteinase inhibitors and wound healing: a novel enhancer of wound strength.

Authors:  M B Witte; F J Thornton; T Kiyama; D T Efron; G S Schulz; L L Moldawer; A Barbul
Journal:  Surgery       Date:  1998-08       Impact factor: 3.982

View more
  6 in total

Review 1.  Is there new hope for therapeutic matrix metalloproteinase inhibition?

Authors:  Roosmarijn E Vandenbroucke; Claude Libert
Journal:  Nat Rev Drug Discov       Date:  2014-11-07       Impact factor: 84.694

2.  Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats.

Authors:  Jing-Wei Mao; Xiao-Mei He; Hai-Ying Tang; Ying-De Wang
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

Review 3.  Digestive Inflammation: Role of Proteolytic Dysregulation.

Authors:  Vincent Mariaule; Aicha Kriaa; Souha Soussou; Soufien Rhimi; Houda Boudaya; Juan Hernandez; Emmanuelle Maguin; Adam Lesner; Moez Rhimi
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

Review 4.  Matrix metalloproteinases in inflammatory bowel disease: an update.

Authors:  Shane O'Sullivan; John F Gilmer; Carlos Medina
Journal:  Mediators Inflamm       Date:  2015-04-08       Impact factor: 4.711

5.  Ilomastat, a synthetic inhibitor of MMPs, prevents lung injury induced by γ-ray irradiation in mice.

Authors:  Xiaoman Li; Dehui Ma; Xiaodan Zha; Dongqin Quan; Dong Pan; Manji Sun; Burong Hu; Baoquan Zhao
Journal:  Oncotarget       Date:  2017-06-15

6.  Novel Barbiturate-Nitrate Compounds Inhibit the Upregulation of Matrix Metalloproteinase-9 Gene Expression in Intestinal Inflammation through a cGMP-Mediated Pathway.

Authors:  Shane O'Sullivan; Jun Wang; Marek W Radomski; John F Gilmer; Carlos Medina
Journal:  Biomolecules       Date:  2020-05-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.